Table of Content


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biospecimen
3.3. Importance of Biospecimen in Drug Discovery and Research
3.4. Factors Affecting the Quality of Biospecimen
3.5. Biospecimen Management
3.6. Regulatory Guidelines
3.7. Outsourcing in Biospecimen Research
3.7.1. Role of Contract Research Organizations in Biospecimen Procurement
3.7.2. Types of Services Offered by Contract Research Organizations
3.8. Future Perspective

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biospecimen Research Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Blood Product(s) Offered
4.2.5. Analysis by Type of Human Tissue(s) Offered
4.2.6. Analysis by Type of Biofluid(s) and Other Biospecimen(s) Offered
4.2.7. Analysis of Type of Analytical Service(s) Offered
4.2.8. Analysis by Type of Sample(s) Offered
4.2.9. Analysis of Accreditation(s) Received
4.2.10. Analysis by Geographical Reach

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Biospecimen Research Service Providers with Biorepositories
5.4.1. Companies Offering Biospecimen Research Services in North America
5.4.2. Companies Offering Biospecimen Research Services in Europe and Asia-Pacific
5.5. Competitiveness Analysis: Biospecimen Research Service Providers without Biorepositories
5.5.1. Companies Offering Biospecimen Research Services in North America
5.5.2. Companies Offering Biospecimen Research Services in Europe

6. BIOSPECIMEN SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. BioChain Institute
6.2.1. Company Overview
6.2.2. Biospecimen Related Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. BioIVT
6.3.1. Company Overview
6.3.2. Biospecimen Related Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Creative Bioarray
6.4.1. Company Overview
6.4.2. Biospecimen Related Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Discovery Life Sciences
6.5.1. Company Overview
6.5.2. Biospecimen Related Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Infinity BiologiX
6.6.1. Company Overview
6.6.2. Biospecimen Related Service Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Precision for Medicine
6.7.1. Company Overview
6.7.2. Biospecimen Related Service Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. PrecisionMed
6.8.1. Company Overview
6.8.2. Biospecimen Related Service Portfolio
6.8.3. Recent Developments and Future Outlook

7. BIOSPECIMEN SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Medicover
7.2.1. Company Overview
7.2.2. Biospecimen Related Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. National BioService
7.3.1. Company Overview
7.3.2. Biospecimen Related Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. REPROCELL
7.4.1. Company Overview
7.4.2. Biospecimen Related Service Portfolio
7.4.3. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biospecimen Research Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Collaborator
8.3.4. Analysis by Type of Service(s) Offered
8.3.5. Analysis by Type of Biospecimen(s) Handled
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.4. Geographical Analysis
8.4.1. Intercontinental and intracontinental Agreements

9. CASE STUDY: MARKET LANDSCAPE OF COMMERCIAL BIOBANKS
9.1. Chapter Overview
9.2. Commercial Biobanks: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Types of Service(s) Offered
9.2.5. Analysis by Types of Biospecimen(s) Handled
9.2.6. Analysis by Therapeutic Area
9.3. Company Competitiveness Analysis
9.3.1. Methodology and Key Parameters
9.3.2. Competitiveness Analysis: Commercial Biobanks with Biorepositories
9.3.3. Competitiveness Analysis: Commercial Biobanks without Biorepositories

10. KEY INSIGHTS
10.1. Chapter Overview
10.2 Grid Analysis: Analysis by Year of Establishment and Type of Analytical Service(s) Offered
10.3. Analysis by Company Size and Therapeutic Area
10.4 Most Active Players: Analysis by Therapeutic Area and
10.5. World Map Representation: Analysis by Location of In-House Biorepositories

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Biospecimen Research Services Market, 2021-2030
11.3.1. Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen
11.3.2. Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area
11.3.3. Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions
11.3.3.1. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries
11.3.3.2. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen
11.3.3.3. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

12. CONCLUSION
12.1. Chapter Overview

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. BioSpecimen Solutions
13.2.1. Overview of Company / Organization
13.2.2. Interview Transcript: Ramachandra Rao, Managing Director and Business Development Head
13.3. National BioService
13.3.1. Overview of Company / Organization
13.3.2. Interview Transcript: Oleg Granstrem, Director of Business Development
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS